Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.47 USD | -7.26% | -6.91% | +203.54% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+203.54% | 2.83B | D | ||
-1.62% | 89.22B | A- | ||
+1.32% | 40.49B | A- | ||
-15.73% | 32.79B | B- | ||
+64.13% | 26.23B | A | ||
-21.28% | 14.52B | C | ||
-8.50% | 13.09B | B- | ||
-44.07% | 11.6B | B | ||
-13.06% | 11.5B | D+ | ||
+4.94% | 8.82B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RNA Stock
- Ratings Avidity Biosciences, Inc.